At a Glance
Shalby Ltd, India’s joint replacement guru, is now flaunting the world’s first fully autonomous robotic joint replacement surgery. Sounds futuristic? Sure. But the stock’s P/E of 1,157 makes even sci-fi fans sweat. Revenue grew 16% YoY to ₹1,087 Cr in FY25, but net profit fell off a cliff to ₹2 Cr. The market seems to be valuing a hospital chain like a unicorn startup. Investors, grab your stethoscopes—this patient’s vitals are confusing.
Introduction
Founded by Dr. Vikram Shah, Shalby earned fame as a global leader in knee replacements. Over time, it expanded to 11 multispecialty hospitals, 5 ortho centers, and a network of 80+ clinics (domestic + international). All good, except the FY25 numbers scream: revenue steady, profits missing in action.
The latest robotic surgery milestone is a PR coup, but does it cure the bleeding bottom line? The market is betting on future tech-driven dominance, ignoring the fact that the present is limping.
Business Model (WTF Do They Even Do?)
- Hospitals: Core revenue driver – orthopaedics, cardiology, oncology, transplants.
- Clinics: Feed the hospitals with patient inflow.
- International
